| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | 746 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| 14.05.25 | XFRA DVL: AUSSETZUNG/SUSPENSION | 345 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILALLIANCE PHARMA... ► Artikel lesen | |
| 13.05.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.05.2025 | 789 | Xetra Newsboard | Das Instrument ZRE CH0042615283 DOCMORRIS AG SF 30 EQUITY wird ex Kapitalmassnahme gehandelt am 13.05.2025 The instrument ZRE CH0042615283 DOCMORRIS AG SF 30 EQUITY is traded ex capital adjustment on... ► Artikel lesen | |
| 10.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 299 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| ALLIANCE PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 323 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 07
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 06.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 376 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 06
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 04.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 336 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 04
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 03.03.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 353 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, March 03
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY... ► Artikel lesen | |
| 28.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 452 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 28
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 27.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 242 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 27
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 26.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 268 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 26
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 25.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 289 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 25
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen | |
| 20.02.25 | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc | 335 | PR Newswire | Samson Rock Capital LLP - Form 8.3 - Alliance Pharma Plc
PR Newswire
LONDON, United Kingdom, February 20
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 40,310 | +0,01 % | Novo Nordisk: Aktie wieder unter Druck - das müssen Anleger jetzt wissen | Die Aktie von Novo Nordisk hat seit ihrem Tief im November vergangenen Jahres eine starke Aufholjagd hingelegt. Zuletzt verlor das Papier allerdings an Schwung. Dabei ist der Titel auch unter eine wichtige... ► Artikel lesen | |
| PFIZER | 23,015 | -0,07 % | Ihre wichtigsten Termine: Frische Quartalszahlen von: Pepsico, PayPal, Pfizer, AMD, Merck & Co und KSB | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
| SANOFI | 80,49 | +0,05 % | Sanofi und Amgen: Droht diesem Ansatz das Aus? AKTIONÄR-Tipp profitiert! | Viele große Pharma- und Biotech-Firmen sind auf der Suche nach neuen Behandlungsansätzen für die Atopische Dermatitis (Neurodermitis). So auch die großen Branchenvertreter Amgen und Sanofi, die mit... ► Artikel lesen | |
| GSK | 25,300 | +1,12 % | Pharmakonzern GSK schlägt sich besser als erwartet - Ziele bestätigt | LONDON (dpa-AFX) - Der Pharmakonzern GSK hat dank eines unerwartet starken Schlussspurts im abgelaufenen Jahr besser abgeschnitten als gedacht. "GSK hat 2025 erneut eine starke Leistung erzielt, die... ► Artikel lesen | |
| INCYTE | 91,10 | -0,65 % | Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? | ||
| IONIS PHARMACEUTICALS | 71,92 | -1,72 % | Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts | ||
| CSPC PHARMA | 1,031 | +0,49 % | HSI Closes at 26,834, Up 59 pts; HSTI Closes at 5,467, Down 59 pts; CSPC PHARMA Up over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Hit New Highs; Market Turnover Rises | ||
| ALNYLAM PHARMACEUTICALS | 277,40 | +0,04 % | Alnylam Unveils 'Alnylam 2030' Strategy To Drive Growth And Innovation | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced its new five-year strategy, 'Alnylam 2030.' The plan is designed to scale the company's operations by achieving leadership... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,150 | -0,32 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,970 | +2,14 % | Trulieve Cannabis Corp.: Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026 | TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,970 | +0,25 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | - Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,550 | -0,63 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 401,30 | -0,62 % | Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth | ||
| WEST PHARMACEUTICAL SERVICES | 206,70 | -1,85 % | Dividendenbekanntmachungen (28.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ANTERO MIDSTREAM CORPORATION US03676B1026 0,225 USD 0,1868 EUR CAL-MAINE FOODS INC US1280302027 0,719 USD 0,597 EUR CLOROX COMPANY US1890541097 1... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,050 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger | CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company"), today announced that it has commenced an exchange offer (the "Offer") involving... ► Artikel lesen |